Cardiac magnetic resonance biomarkers as surrogate endpoints in cardiovascular trials for myocardial diseases-Reference-Cited by-同舟云学术

Cardiac magnetic resonance biomarkers as surrogate endpoints in cardiovascular trials for myocardial diseases

Published:2023-09-13 Issue:45 Volume:44 Page:4738-4747
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Benz Dominik C¹,Gräni Christoph²,Antiochos Panagiotis³,Heydari Bobak⁴,Gissler Mark Colin⁵,Ge Yin⁶,Cuddy Sarah A M¹,Dorbala Sharmila¹,Kwong Raymond Y¹^ORCID

Affiliation:

1. Noninvasive Cardiovascular Imaging Section, Cardiovascular Division, Department of Medicine and Department of Radiology, Brigham and Women’s Hospital , 75 Francis Street, Boston, MA 02115 , USA

2. Department of Cardiology, Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland

3. Cardiology and Cardiac MR Centre, University Hospital Lausanne , Lausanne , Switzerland

4. Cardiovascular Division, Department of Medicine, University of Calgary , Calgary, Alberta , Canada

5. Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg , Freiburg , Germany

6. Terrence Donnelly Heart Center, St Michael’s Hospital , Toronto , Canada

Abstract

Abstract Cardiac magnetic resonance offers multiple facets in the diagnosis, risk stratification, and management of patients with myocardial diseases. Particularly, its feature to precisely monitor disease activity lends itself to quantify response to novel therapeutics. This review critically appraises the value of cardiac magnetic resonance imaging biomarkers as surrogate endpoints for prospective clinical trials. The primary focus is to comprehensively outline the value of established cardiac magnetic resonance parameters in myocardial diseases. These include heart failure, cardiac amyloidosis, iron overload cardiomyopathy, hypertrophic cardiomyopathy, cardio-oncology, and inflammatory cardiomyopathies like myocarditis and sarcoidosis.

Funder

Swiss National Science Foundation

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

https://academic.oup.com/eurheartj/article-pdf/44/45/4738/53969436/ehad510.pdf

Reference62 articles.

1. Sudden cardiac death in ischemic heart disease: from imaging arrhythmogenic substrate to guiding therapies;Gräni;JACC Cardiovasc Imaging,2020

2. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial;Budoff;Eur Heart J,2020

3. Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I—analytical validation and clinical qualification;Puntmann;J Cardiovasc Magn Reson,2018